Biomarkers for Alzheimer's Disease: Academic, Industry and Regulatory Perspectives

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2010 Jul 2

PMID 20592748

Citations 222

Authors

Harald Hampel

Richard Frank

Karl Broich

Stefan J Teipel

Russell G Katz

John Hardy

Karl Herholz

Arun L W Bokde

Frank Jessen

Yvonne C Hoessler

Wendy R Sanhai

Henrik Zetterberg

Janet Woodcock

Kaj Blennow

Affiliations

Soon will be listed here.

Abstract

Advances in therapeutic strategies for Alzheimer's disease that lead to even small delays in onset and progression of the condition would significantly reduce the global burden of the disease. To effectively test compounds for Alzheimer's disease and bring therapy to individuals as early as possible there is an urgent need for collaboration between academic institutions, industry and regulatory organizations for the establishment of standards and networks for the identification and qualification of biological marker candidates. Biomarkers are needed to monitor drug safety, to identify individuals who are most likely to respond to specific treatments, to stratify presymptomatic patients and to quantify the benefits of treatments. Biomarkers that achieve these characteristics should enable objective business decisions in portfolio management and facilitate regulatory approval of new therapies.

Citing Articles

Lipidopathy disrupts peripheral and central amyloid clearance in Alzheimer's disease: Where are our knowledge.

Darabi S, Charkhat Gorgich E, Moradi F, Rustamzadeh A IBRO Neurosci Rep. 2025; 18:191-199.

PMID: 39906286 PMC: 11791331. DOI: 10.1016/j.ibneur.2025.01.004.

Biofluid biomarkers for Alzheimer's disease: past, present, and future.

An C, Cai H, Ren Z, Fu X, Quan S, Jia L Med Rev (2021). 2024; 4(6):467-491.

PMID: 39664082 PMC: 11629312. DOI: 10.1515/mr-2023-0071.

Association of liver function markers and apolipoprotein E ε4 with pathogenesis and cognitive decline in Alzheimer's disease.

Han S, Lee S, Kim J, Lee J, Park Y, Kim S Front Aging Neurosci. 2024; 16:1411466.

PMID: 39114318 PMC: 11303325. DOI: 10.3389/fnagi.2024.1411466.

Automated diagnosis of schizophrenia based on spatial-temporal residual graph convolutional network.

Xu X, Zhu G, Li B, Lin P, Li X, Wang Z Biomed Eng Online. 2024; 23(1):55.

PMID: 38886737 PMC: 11181588. DOI: 10.1186/s12938-024-01250-y.

Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective.

Shukla D, Suryavanshi A, Bharti S, Asati V, Mahapatra D Curr Top Med Chem. 2024; 24(19):1699-1737.

PMID: 38566385 DOI: 10.2174/0115680266299847240328045737.

References

Gilman S, Koller M, Black R, Jenkins L, Griffith S, Fox N . Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005; 64(9):1553-62. DOI: 10.1212/01.WNL.0000159740.16984.3C. View

Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel S . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006; 129(Pt 11):3035-41. DOI: 10.1093/brain/awl269. View

Sankaranarayanan S, Holahan M, Colussi D, Crouthamel M, Devanarayan V, Ellis J . First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther. 2008; 328(1):131-40. DOI: 10.1124/jpet.108.143628. View

Rowe C, Ackerman U, Browne W, Mulligan R, Pike K, OKeefe G . Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008; 7(2):129-35. DOI: 10.1016/S1474-4422(08)70001-2. View

Visser P, Verhey F, Knol D, Scheltens P, Wahlund L, Freund-Levi Y . Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009; 8(7):619-27. DOI: 10.1016/S1474-4422(09)70139-5. View

Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A . Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med. 2006; 44(12):1472-80. DOI: 10.1515/CCLM.2006.258. View

de Leon M, DeSanti S, Zinkowski R, Mehta P, Pratico D, Segal S . Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2005; 27(3):394-401. DOI: 10.1016/j.neurobiolaging.2005.07.003. View

Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K . Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol. 2000; 43(3):155-60. DOI: 10.1159/000008156. View

Fox N, Black R, Gilman S, Rossor M, Griffith S, Jenkins L . Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005; 64(9):1563-72. DOI: 10.1212/01.WNL.0000159743.08996.99. View

10.

Hampel H, Burger K, Teipel S, Bokde A, Zetterberg H, Blennow K . Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008; 4(1):38-48. DOI: 10.1016/j.jalz.2007.08.006. View

11.

Siemers E . How can we recognize "disease modification" effects?. J Nutr Health Aging. 2009; 13(4):341-3. DOI: 10.1007/s12603-009-0036-7. View

12.

Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K . Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry. 2007; 64(6):718-26. DOI: 10.1001/archpsyc.64.6.718. View

13.

Blennow K, Hampel H . CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003; 2(10):605-13. DOI: 10.1016/s1474-4422(03)00530-1. View

14.

Leber P . Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 5:S10-21; discussion S37-9. View

15.

Kauwe J, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P . Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A. 2008; 105(23):8050-4. PMC: 2430357. DOI: 10.1073/pnas.0801227105. View

16.

Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K . Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007; 13(11):1359-62. DOI: 10.1038/nm1653. View

17.

Villemagne V, Pike K, Darby D, Maruff P, Savage G, Ng S . Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008; 46(6):1688-97. DOI: 10.1016/j.neuropsychologia.2008.02.008. View

18.

von der Kammer H, Mayhaus M, Albrecht C, Enderich J, Wegner M, Nitsch R . Muscarinic acetylcholine receptors activate expression of the EGR gene family of transcription factors. J Biol Chem. 1998; 273(23):14538-44. DOI: 10.1074/jbc.273.23.14538. View

19.

Logothetis N . The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Philos Trans R Soc Lond B Biol Sci. 2002; 357(1424):1003-37. PMC: 1693017. DOI: 10.1098/rstb.2002.1114. View

20.

Ewers M, Teipel S, Dietrich O, Schonberg S, Jessen F, Heun R . Multicenter assessment of reliability of cranial MRI. Neurobiol Aging. 2005; 27(8):1051-9. DOI: 10.1016/j.neurobiolaging.2005.05.032. View